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Autism spectrum disorders
utism,also referred to as autistic disorder (des-
ignated as OMIM #209850, by Online Mendelian
Inheritance in Man,an online database of human genes
and genetic phenotypes), is a developmental neuropsy-
chiatric disorder that was first described in 1943 by Dr
Leo Kanner.
1 DSM-IV (Diagnostic and Statistical
Manual,4th Edition,American Psychiatric Association),
or similar criteria are used for diagnosis of autism and
other disorders in this spectrum, referred to as the per-
vasive developmental disorders (PDD). DSM-IV crite-
ria for autism include onset by age 3, impairments in
social interaction and in social communication, as well
as repetitive and stereotypic patterns of behaviors or
restricted interests. Asperger syndrome represents a
higher-functioning form of ASD.Pervasive developmen-
tal disorder-not otherwise specified (PDD-NOS) also
involves deficits in all three domains (social interaction,
social communication, characteristic behaviors/inter-
ests),but the deficits do not reach threshold criteria for
an autism diagnosis.In this review, Asperger syndrome,
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Recent studies in autism spectrum disorders (ASDs) sup-
port an important role for multiple rare variants in these
conditions. This is a clinically important finding, as, with
the demonstration that a significant proportion of ASDs
are the result of rare, etiological genetic variants, it
becomes possible to make use of genetic testing to sup-
plement behavioral analyses for an earlier diagnosis. As
it appears that earlier interventions in ASDs will produce
better outcomes, the development of genetic testing to
augment behaviorally based evaluations in ASDs holds
promise for improved treatment. Furthermore, these
rare variants involve synaptic and neuronal genes that
implicate specific pathways, cells, and subcellular com-
partments in ASDs, which in turn will suggest novel ther-
apeutic approaches in ASDs. Of particular recent inter-
est are the synaptic cell adhesion and associated
molecules, including neurexin 1, neuroligin 3 and 4, and
SHANK3, which implicate glutamatergic synapse abnor-
malities in ASDs. In the current review we will overview
the evidence for a genetic etiology for ASDs, and sum-
marize recent genetic findings in these disorders. 
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:35-43.and PDD-NOS will be referred to collectively as autism
spectrum disorders (ASDs).
Epidemiological twin studies of ASDs
ASD twin studies have shown that the concordance rate
for monozygotic (MZ) and dizygotic (DZ) twins ascer-
tained for ASD differed substantially, with an MZ:DZ
ratio of approximately 10 to 1.
2-5 In these studies, esti-
mates of heritability (ie,the proportion of the variance
explained by genetic causes) in ASDs were above 93%,
with little or no evidence for shared or nonshared envi-
ronmental factors.These conclusions agree with multiple,
independent family studies, which show a very strong
aggregation of ASDs within families, consistent with a
genetic etiology for ASDs,with little support for environ-
mental factors (eg, ref 6). Note, however, that risk for
ASD is not transmitted in a simple manner.This is exem-
plified both in the family studies (eg, ref 6) and in the
genetic conditions that can result in an ASD diagnosis,
which are typically non-Mendelian and include X-linked
inheritance,de novo mutations,and chromosomal alter-
ations,as well as transmission of unbalanced transloca-
tions (see below).
Common variant and multiple rare 
variant hypotheses
In common genetic diseases, such as ASDs, there have
been two models for genetic etiology,which are not nec-
essarily mutually exclusive.These are the common dis-
ease/common variant (CD/CV) and the common dis-
ease/rare variant (CD/RV) models (the latter is also
called the multiple rare variant/MRV model).
7-10 CVs are
genetic variants that are found to be more widely distrib-
uted in the population and are associated with a modest
increase in risk,and typically associated with odds ratios
(ORs) less than 2 and often with ORs in the 1.1-1.3
range.The interaction of a CV with other CVs and with
other factors can act together to increase risk. In con-
trast, in the MRV model a large number of rare, and
even very rare,variants underlie the disorder.These RVs
are typically associated with ORs that can be quite sub-
stantial, and may contribute the major part of the sus-
ceptibility for a given individual.At the extreme, RVs
have high ORs and are equivalent to rare deleterious
mutations.Population attributable risk (PAR,ie,the pro-
portion of disease in a population that can be attributed
to a given etiological agent) can be quite high for CVs,
irrespective of their lower ORs,as the variants are more
widespread,while RVs,even with high ORs,will have a
low PAR when considered individually. With MRVs,
PAR becomes significant when considering the RVs
together. CVs and RVs will be treated very differently
in the clinical setting, and also require alternative
approaches for their discovery.
9 For these reasons,under-
standing which mechanism(s) underlie a given disease
entity can have important ramifications. The CD/CV
hypothesis had been challenged from a population
genetic perspective
7,8,10 and, as we will note below, there
was and is increasing evidence that ASDs can result
from RVs, leading to a MRV model to explain much of
the ASD risk.
Methods for identifying genetic loci for ASDs
Genomic variations leading to large-scale deletion and
duplications associated with ASDs were first identified
by karyotyping (eg, ref 11). More recently, the use of
genome-wide arrays to query for copy number variants
(CNVs) has identified additional genomic variations
associated with ASDs (see below).As these methods
evolve and their resolution increases, additional
genomic imbalances associated with ASD will certainly
be identified. Similarly, the search for both single-base
RVs and CVs in disease has also been profoundly
affected by the evolution of technology.In the past,such
studies focused on CVs or RVs in candidate genes,iden-
tified based on biological grounds and/or positional
information following linkage analyses (eg,ref 12).With
the evolution of genome-wide single-nucleotide poly-
morphism (SNP) genotyping, the focus on CV SNPs
that increase risk for disease has shifted to genome-
wide association analyses (GWAS). Similarly, with the
development of high-throughput sequencing,hundreds
of genes can be sequenced for RVs in ASDs.In the fol-
lowing sections, we will review RVs associated with
ASDs, including genetic conditions, CNVs, and muta-
tions (Table I).
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Selected abbreviations and acronyms
ASD autism spectrum disorders
CV common variant
RV rare variant
OR odds ratio
CNV copy number variantGenetic conditions associated with ASDs
A variety of genetic conditions,of which most can be syn-
dromic (ie, associated with recognizable clinical signs,
including dysmorphic, metabolic, or neurological fea-
tures) can present with ASDs.These include 15q11-13
duplications,22q11 deletion/DiGeorge syndrome,22q11
duplication syndrome,22q13 deletion syndrome,adeny-
losuccinate lyase deficiency,Angelman syndrome (AS),
Cohen syndrome,Down syndrome,Fragile X syndrome,
MECP2-related disorders,neurofibromatosis,untreated
phenylketonuria,Potocki-Lupski syndrome,Prader-Willi
syndrome (PWS), PTEN-associated syndromes, San
Filippo syndrome, Smith-Magenis syndrome, Smith-
Lemli-Opitz syndrome,Sotos syndrome,tuberous sclero-
sis,and Williams syndrome.
13-17 For individuals with these
syndromes,a proportion of cases can have an ASD diag-
nosis
18,19 and for some of these conditions, there have
been examples of individuals identified with a primary
diagnosis of ASD,and only later was the syndrome iden-
tified (that is to say that a proportion of individuals with
assessed with idiopathic ASDs may have some of these
conditions,perhaps without a typical syndromal presen-
tation).
In some cases,the genetics of the ASD-associated syn-
drome is well understood. Fragile X syndrome (FXS),
caused by a trinucleotide repeat expansion in the fragile
X mental retardation 1 (FMR1) gene at Xq27.3,is among
the most common syndromes associated with ASDs.
Among individuals with FXS,ASD symptoms occur in
one quarter to one third of subjects,
20,21 while the preva-
lence of FXS is estimated to be 2% among individuals
identified with an ASD.AS and PWS,as well as 15q11-13
duplications,collectively are also common ASD-associ-
ated syndromes,of which each has different molecular
etiology.
15,22,23 Rett syndrome,listed among the PDDs in
DSM-IV, is caused by mutation in the gene encoding
methyl-CpG-binding protein-2 (MECP2) and a propor-
tion of girls identified with an ASD are found to have
Rett syndrome.
24
Novel CNVs associated with ASDs identified
by genome-wide scanning
Novel CNVs in ASDs
Whole genome scans for CNVs use genome-wide array-
based methods to search for deletions and duplications.
This approach complements karyotyping and targeted
methods such as fluorescence in situ hybridization
(FISH).
25There have been several such studies in idio-
pathic ASDs in the past year,
26-31 along with additional
such studies in syndromal ASDs.
32 Several general find-
ings are worth noting (see ref 33 for a more detailed sum-
mary).First,there are increased rates of de novo CNVs
in ASDs, particularly in simplex families, reaffirming
what was clear from medical conditions associated with
ASDs,ie,that de novo changes are significant factors in
ASD.Second,there appear to be increases in the num-
bers of de novo CNVs in the syndromal cases. Third,
amongst inherited CNVs,there were individuals (parents
or sibs) with the CNV without an apparent diagnosis,
consistent with variable expressivity of many known
genetic disorders.There were even families where a likely
causal CNV was found in one affected child but not in
another,suggesting independent etiologies.Finally,there
were some CNVs that were recurrent (see below) but
there were some CNVs that appeared likely to be etio-
logically significant but that were identified only once.
Algorithms are being developed by molecular cytoge-
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Genetic etiology Estimated prevalence in ASD
Karyotype abnormalities 5-10%
Fragile X syndrome 2%
15q abnormalities 2%
Tuberous sclerosis 1%
16p11 deletions 1%
22q13 deletions/SHANK3 abnormalities 0.75%
22q11 abnormalities 0.50%
Rett syndrome 0.10%
c30rf58 deletions, homozygous Rare
CNTN4 deletions Rare
DPP10 deletions Rare
DPP6 deletions Rare
NHE9 deletions, homozygous Rare
NLGN deletions/mutations Rare
NRXN1 deletions Rare
PCDH10 deletions, homozygous Rare
PCDH9 deletions Rare
PTEN mutations Rare
Table I. Multiple rare variants in autism spectrum disorders (ASDs). While
epidemiologically rigorous studies have yet to be carried out,
there are reasonable estimates for the prevalence of some of the
genetic contributors to ASDs. Some of the more common ones
are shown here, together with some of the rare variants identi-
fied in recent studies. neticists to weight such nonrecurrent CNVs to estimate
the likelihood that they are etiologically relevant,consid-
ering such factors as size of the CNV,whether it is a dele-
tion or duplication,de novo or inherited origin,gene con-
tent,and overlap with known genetic disorders.
CNTN4
Disruption of CNTN4,coding for the CAM contactin 4
which is involved in the formation,maintenance,and plas-
ticity of neuronal networks,has been shown to be a likely
cause for cognitive aspects of 3p deletion syndrome,which
presents with developmental delay.
34-36 Recently,deletions
in cases with idiopathic ASDs indentified CNVs at the
CNTN4 locus in two unrelated individuals.
37
NRXN1
The first large, genome-wide SNP microarray study
(using earlier generation arrays and hence just 10 000
SNPs) was conducted in over 1000 ASDs families by the
Autism Genome Project (AGP) Consortium.
27With strin-
gent filtering, a total of 254 CNVs were identified as
being most relevant to ASD. The AGP identified two
female sibs with ASD harboring identical de novo dele-
tions at 2p16,over a portion of the neurexin 1 (NRXN1)
gene.Additional groups have since confirmed a role for
NRXN1 deletions in ASD.
31,38-41 Neurexins function in the
vertebrate nervous system as CAMs with critical roles in
synaptogenetis and bind to neuroligins,which represent
another family of ASD genes (see below).
16p11 CNVs 
Another interesting CNV in ASD is in the 16p11 region,
which occurs in up to 1% of subjects with ASDs. First
reported in the studies by Sebat et al
26 and Christian et
al,
28,29 this CNV was also identified in a screen by Weiss et
al,
30 in which they investigated 751 multiplex ASD families
using 500 000 SNP markers and found a recurrent 16p11
deletion (note that some of these studies relied in part on
the Autism Genetic Reource Exchange (AGRE) collec-
tion and were hence not fully independent) The CNV has
recurrent break points defined by low copy repeats and
includes ~30 genes,and multiple studies are being carried
out in multiple labs to understand whether this represents
a contiguous gene syndrome or whether one or two genes
in the interval are responsible for the phenotype.
The synaptic genes DPP6, DPP10, and PCDH9
An additional SNP microarray study using 500 000 SNP
markers investigated 427 ASD families.
31 This study
described many potentially interesting CNVs (277
CNVs in 44% of ASD families) (including the 16p11
deletion). Genes within those CNVs included the
synaptic genes SHANK3, NLGN4, and NRXN1 (see
above and below) and additional synaptic genes,includ-
ing DPP6, DPP10, and PCDH9.The dipeptidyl pepti-
dases (DPP) DPP6 and DPP10, which actually lack
DPP activity and have therefore been proposed to be
renamed DPP-like,complex with Kv4 potassium chan-
nels and potassium-channel interacting proteins
(KChIPs) to regulate channel activity.
42 DPP6 and
DPP10 are hence important regulators of neuronal
excitability, particularly as related to the regulation of
firing frequency, integration of signal across dendrites,
and neuronal plasticity. PCDH9 codes for protocad-
herin 9,a member of the cadherin family of homotypic
CAMs, which shows localized expression in particular
cortical and thalamic regions in development.
43
Homozygous deletions in PCDH10, DAI1, and NHE9
Recently,homozygosity mapping was used to identify a
novel large homozygous deletion at 3q24 implicating the
c3orf58 locus (or deleted in autism 1, DIA1), which
encodes a protein localized to the Golgi apparatus,and
a homozygous deletion at 4q28 implicating the protocad-
herin 10 (PCDH10) locus,
44 which encodes a cadherin
superfamily protein essential for normal forebrain axon
outgrowth.
45 Gene expression studies in rat neurons
showed that expression of these genes is regulated by
neuronal activity and hence may be involved in synaptic
changes related to learning.A gene adjacent to DIA1,the
Na+/H+ exchanger 9 (NHE9) encoding a membrane
protein that exchanges intracellular H+ for extracellular
Na+,was identified with a loss-of-function mutation in
autism patients with unrelated parents.
Novel mutations associated with ASDs
SHANK3
The 22q13 deletion syndrome is characterized by global
developmental delay,hypotonia,delayed or absence of
speech,normal to accelerated growth and head circum-
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ference,mild dysmorphic face,and ASD-like behaviors,
46
and there is good evidence,based on the presence of a
recurrent breakpoint,that SHANK3 is the critical gene
in this syndrome.
47A recent study asked whether muta-
tions in SHANK3 or chromosomal changes at the
SHANK3 locus were directly associated with idiopathic
ASDs, making use of FISH analysis and/or direct
sequencing in about 300 cases.
48 The study identified
three families with ASD that showed alterations:a fam-
ily with a proband carrying a de novo deletion in intron
8,removing 142 kb of 22q13;a family with two affected
brothers with a nucleotide insertion,creating a frameshift
that modified the C-terminal sequence of the protein
(derived from germline mosaicism in the mother);and,a
family with both monosomy (resulting in autism) or tri-
somy of 22q13 (resulting in Asperger syndrome) in
affected siblings,both arising from a paternal transloca-
tion.A subsequent study found one de novo SHANK3
mutation and two 22q13 deletions in 400 ASD subjects
(and an additional deletion in a different cohort).
49As in
the first study,one deletion arose from a paternal translo-
cation, resulting in a child with monosomy at the
SHANK3 locus and a child with trisomy at this locus.The
monosomy was associated with autism,while the mono-
somy was associated with attention-deficit hyperactiv-
ity disorder (ADHD).A recent study found one de novo
deletion and one missense change (the latter transmitted
from a father with epilepsy) in 427 ASD cases.
50 CNVs at
the SHANK3 locus have also been identified in the
genome-wide studies noted above.
31 Altogether, these
results indicate that haploinsufficiency of SHANK3 can
cause a monogenic form of ASD with frequency of about
0.5% to 1% of ASD cases.Furthermore,trisomy at this
locus appears to result in less severe phenotypes,includ-
ing Asperger syndrome and ADHD.
SHANK3 is a synaptic scaffolding protein that is abun-
dant in the postsynaptic density (PSD).It has multiple
protein interaction domains,interfacing between gluta-
mate (and likely other) receptor complexes and actin
regulatory proteins, and therefore appears to be well
suited to playing a role in spine morphogenesis and
synaptic plasticity.
51,52 When overexpressed in cultured
hippocampal neurons,SHANK3 promoted the enlarge-
ment of dendritic spines,
53 while disruption of the related
Shank1 in mice led to smaller dendritic spines and
reduced synaptic transmission,along with altered cogni-
tive processes.
54 Dramatically,expression of SHANK3 in
aspiny cerebellar neurons promoted spine formation and
the recruitment of glutamate receptors to the synapse,
directing implicating SHANK3 in the formation and
function of glutamatergic synapses.
55
NLGN3/4
Neuroligins (NLGNs), which are SHANK3- and
NRXN1-interacting proteins, are postsynaptic CAMs
that support synapse—including glutamatergic synapse—
formation. There are five homologs in the human
genome, with NLGN3 and NLGN4X found on the X-
chromosome (at Xq13 and Xp22.3, respectively), and
NLGN4Y on the Y chromosome. Screening for muta-
tions in these genes in over 150 cases led to the identifi-
cation of two de novo mutations,including a frameshift
mutation in NLGN4 and a C-T transition in NLGN3 that
led to a R451C change.
56 In another study,a mutation in
NLGL4 that leads to a premature stop codon was found
in a large pedigree.
57While the mutation had very high
penetrance,expressivity was variable with the 10 males
having mental retardation (MR) and/or ASD.NLGN4
deletions in ASDs were observed in one recent study,
31
but other studies have suggested that NLGN4 deletions
can be associated with little or differing psychiatric phe-
notypes in some males,including tics,Tourette syndrome,
and ADHD.
58-60A recent study suggests that mutations in
NGLN4Y might also result in an ASD.
34
Disruption of Nlgn4x in mice leads to deficits in recipro-
cal social interactions and communication.
61 It has been
reported that introducing the R451C mutation in murine
Nlgn3 was reported to result in impaired social interac-
tions with an increase in inhibitory synaptic transmis-
sion
62;however,these behavioral deficits were not seen in
an independent study.
63
CNTNAP2 
Cortical dysplasia-focal epilepsy syndrome was first
described in 2006 in Amish children displaying cortical
dysplasia,focal epilepsy,relative macrocephaly,dimin-
ished deep-tendon reflexes,language regression,MR,and
ASD.
64The disorder is recessive and caused by mutations
in the CNTNAP2 gene,which codes for contactin-asso-
ciated protein-like 2 (CASPR2) that is involved in local-
ization of voltage-gated potassium channels (K(v)1.1) at
the juxtaparanodes of the nodes of Ranvier.Three recent
studies assessed this gene in ASDs.First,following up on
a linkage result of a language-related autism QTL,it wassuggested that common variants of CNTNAP2 may
increase risk for ASDs in male-only families,and it was
shown that CNTNAP2 is expressed in language- and cog-
nition-related circuits.
65This finding was also observed in
a related study using overlapping AGRE families.
66
Finally,rare variants of the CNTNAP2,and particularly
the I869T variant, also show some association with
ASD.
67
PTEN
Our own studies on PTEN mutations in ASD can serve
to highlight the clinical value of identifying mutations in
ASD.
68 Mutations in the PTEN gene are associated with
a broad spectrum of disorders, including Cowden syn-
drome (CS), Bannayan-Riley-Ruvalcaba syndrome,
Proteus syndrome,and Lhermitte-Duclos disease,as well
as ASDs (reviewed in ref 68).We surveyed head circum-
ference information from hundreds of subjects with ASD
and sequenced the PTEN gene in 88 individuals showing
macrocephaly (defined as a head circumference ≥2 stan-
dard deviations above the mean). We identified a de
novo missense mutation (D326N) in a highly conserved
amino acid in a 5-year-old boy with autism,MR,language
delay,and extreme macrocephaly (+9.6 SD).The identi-
fication of this mutation can give important information
to the family with regard to recurrence risk, and also
improve the care of the affected boy because an appro-
priate surveillance strategy for PTEN-mutation-related
conditions can be initiated.
Etiological yield in ASDs
The importance of evaluating ASD-associated syn-
dromes in the clinical context needs to be emphasized.A
recent study used a three-tiered neurogenetic evaluation
scheme to evaluate 32 patients with a behavioral diagno-
sis of an ASD.An overall medical and/or genetic diagnos-
tic yield of 40% was found,
69 although more typical stud-
ies have a lower yield (see above) and no published study
has done this with modern molecular methods with an
epidemiological valid cohort.As our knowledge increases
and methods further evolve,it will become straightfor-
ward to carry out a comprehensive scan for genetic dis-
orders in ASD,facilitating diagnosis,identifying medical
concerns associated with syndromes,and defining sub-
groups that might be more responsive to specific thera-
peutic approaches (see below).
Conclusions
There is overwhelming evidence that ASDs are genetic
disorders,but the genetic mechanisms are varied,involv-
ing both inherited and de novo changes,as well as muta-
tions,trinucleotide repeats,CNVs,and larger chromoso-
mal abnormalities.An increasing proportion of ASD is
being recognized as being the result of RVs associated
with high ORs.
Table I summarizes estimates the prevalence of some
genetic variants in subjects ascertained for ASDs.Note
that an additional 5% to 10% of cases have been iden-
tified with CNVs that are not recurrent but are likely
pathogenic (based on size,de novo origin,etc).This sug-
gests that,even with our current knowledge,20% to 30%
of ASDs can be given an etiological diagnosis using stan-
dard clinical genetic methods,including high-resolution
karyotyping,array comparative genomic hybridization
(array CGH),and MECP2 sequencing in girls,
70,71 as well
as PTEN sequencing in individuals with extreme macro-
cephaly
68 and the examination of methylation and gene
dosage abnormalities in 15q.
72
It is of interest that synaptic and neuronal cell adhesion
molecules (CAMs) are appearing in RVs in ASDs.It is
also of interest that cytoplasmic proteins that bind to
synaptic CAMs are also being identified.These findings
will lead to evidence-based hypotheses as to the molec-
ular and cellular deficits underlying ASDs with differing
etiologies.Of particular interest is the replicated finding
of SHANK3 deficits, which directly implicates gluta-
matergic synapse dysfunction in both autism and
Asperger syndrome. This finding is supported by the
replicated findings with NRXN1 and NLGN3/4,which
can also play a role in excitatory synapse formation,
maintenance,and plasticity.
As the technology for detecting smaller and smaller dele-
tions and duplications improves and as people take
advantage of the newest technologies of ultradeep
sequencing,the search for RVs in ASDs will enter a new
phase.In this context,a useful model for the genetic and
genomic architecture of ASD might be that of MR. In
MR several hundred genes have been found and the evi-
dence is strong that there are more genes to be found.
Not only are some of the MR genes associated with
ASDs,but as we discover more and more rare variants in
autism,it is becoming increasingly clear that the architec-
ture of MR could represent a good model as to what we
will find in ASDs.
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40There is empirical evidence that ASD can,in some cases,
respond to intensive behavioral interventions.
73 Thus,
identifying individuals with greater risks of ASD at an
earlier age will have important clinical and practical
implications.It will require the simultaneous analysis of
multiple genetic and genomic mechanisms before effec-
tive tools for the molecular assessment of ASD etiology,
used in conjunction with behavioral assessment,can be
applied in a widespread manner.
As ASD loci continue to be identified, animal models
that recapitulate the genetic change(s) can be developed.
These models can clarify the function of the gene prod-
ucts in vivo, and will ultimately be useful to evaluate
novel pharmaceutical interventions.An exciting devel-
opment which will serve as a useful model going forward
is the elaboration of the mGluR theory of FXS.
74This in
turn has led to the initiation of a recent large-scale clin-
ical trial in FXS in which a reverse agonist of mGlu5 is
being assessed in FXS.As additional RVs associated with
ASDs are identified,novel therapeutic approaches will
arise,some which may be specific to a given RV (“per-
sonalized medicine”) and some that might prove effec-
tive across ASDs with differing etiologies. ❏
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Múltiples variantes raras en la etiología de
los trastornos del espectro autista
Los estudios recientes en los trastornos del espectro
autista (TEA) refuerzan el importante papel que tie-
nen múltiples variantes raras en estos cuadros. Este
es un hallazgo clínicamente importante, ya que con
la demostración de que un porcentaje significativo
de TEA son el resultado de una etiología de varian-
tes genéticas raras, puede llegar a ser posible el
empleo de pruebas genéticas como complemento
al análisis de la conducta para un diagnóstico más
precoz. Ya que se ha observado que las intervencio-
nes más precoces en los TEA generan mejores evo-
luciones, el desarrollo de pruebas genéticas comple-
mentarias a las evaluaciones basadas en la conducta
en los TEA promete un mejor tratamiento. 
Además estas variantes raras comprenden genes
sinápticos y neuronales que incluyen vías específi-
cas, células y compartimentos subcelulares en los
TEA, lo que a la vez sugiere nuevas aproximaciones
terapéuticas en los TEA. Recientemente  ha tenido
un especial interés la adhesión celular sináptica y las
moléculas asociadas, que incluyen la neurexina 1,
las neuroliginas 3 y 4, y SHANK3 lo que se traduce
en alteraciones de la sinapsis glutamatérgica en los
TEA. En este artículo se revisa la evidencia de la
etiología genética para los TEA y se resumen los
hallazgos genéticos recientes en estos trastornos.  
Étiologie des troubles autistiques : 
beaucoup de variants rares
Les études récentes plaident en faveur de l’exis-
tence de nombreux variants rares dans les troubles
du spectre autistique (TSA). Ce résultat est clinique-
ment important car si une proportion significative
de TSA provient de variants génétiques étiolo-
giques rares, il devient possible d’utiliser des tests
génétiques pour éviter les analyses comportemen-
tales pour effectuer un diagnostic plus précoce.
Comme il semble qu’intervenir tôt dans les TSA
donne des évolutions plus favorables, le dévelop-
pement de tests génétiques pour enrichir les éva-
luations basées sur le comportement permet d’es-
pérer un traitement meilleur. De plus, ces variants
rares portent sur des gènes synaptiques et neuro-
naux qui concernent des voies, des cellules, et des
compartiments sous-cellulaires spécifiques des TSA,
suggérant en retour de nouvelles approches théra-
peutiques référencées dans ce domaine. Les molé-
cules d’adhésion cellulaire synaptique et associées,
(comme la neurexine 1, les neuroligines 3 et 4 et
SHANK3) qui impliquent les anomalies glutamater-
giques de la synapse dans les TSA, sont particuliè-
rement intéressantes selon des données récentes.
Dans cet article, nous allons donner une vue d’en-
semble des arguments en faveur d’une étiologie
génétique des TSA et nous résumerons les résultats
génétiques récents les concernant.
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